Close Menu

Share with your friends

Close

Imugene Limited (ASX: IMU)

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease.

To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures.

One $30 million capped ASX junior may have a unique solution.

This ASX stock is attempting to develop cancer treatment drug that could be first in class, cost effective and has a unique difference.

The company is working in the immunotherapy space, an area touted as ‘a breakthrough’ treatment set to ‘revolutionise’ the oncological industry.

The immunotherapy space has attracted billion dollar Big Pharma deals. In fact, 20% of the top 10 Big Pharma deals in 2015 were in this space. 

By developing its unique treatment, this company is not only looking to help cancer sufferers, but it could commercialise its drug, if it can attract Big Pharma dollars.

This is in a field where the average total deal size is $514.6 million – many times this company’s current $30 million market cap.

The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

At the helm of this tightly held company are two veterans of the industry who have already been involved in billion dollar deals.

With cash in the bank, the potential development of a unique treatment that could have a major positive affect on cancer management, and plenty of newsflow to come from its imminent trials, 2017 promises to be a busy and potentially very successful year for this company.

 

Latest Article

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.

Mar 16, 2017 Continue Reading

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

[gravityform id="9" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.
[gravityform id="9" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.